tadalafil dosage - viagra - augmentin uses - http://sildenafilgeneric-citrate.com/ - levitra 20mg vs viagra 100mg - furosemide for dogs - lisinopril hctz - cialis generic - gabapentin 300mg - doxycycline hyclate 100mg

Latest News

As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection

As Diabetes Becomes Global Epidemic, PharmaCyte Biotech’s Insulin Producing Cells Receive 20 Years of Protection

Written by Ι Stock Market Media — July 19, 2016

Worldwide the number of people living with diabetes has reached 422 million, and if the current trend continues, over 700 million people are expected to be living with diabetes by 2025. Diabetes has clearly become a healthcare crisis on a global scale, and PharmaCyte Biotech (OTCQB: PMCB) recently received some good news in the form of patent protection that will help the company do its part in bringing a treatment to tens of ...

Read More →
0

Pocket Starships Could be SPYR’s Ticket to Growing Revenues in a Fast-Growing Digital Games Market

Pocket Starships Could be SPYR’s Ticket to Growing Revenues in a Fast-Growing Digital Games Market

Written by Ι Stock Market Media — May 26, 2016

When SPYR, Inc. (OTCQB: SPYR) moved into the mobile game & app development and publishing industry, a decision was made early on to surround the company with successful industry names, and to partner with reputable third-party developers to publish quality mobile games. Well, the company has done both, and its recent agreement to publish the free-to-play Massively Multiplayer Online Game or MMO, Pocket Starships, may just lead to the game becoming SPYR’s “diamond ...

Read More →
0

SPYR’s Paul Thind Discusses Company’s Future in Mobile Games Industry

SPYR’s Paul Thind Discusses Company’s Future in Mobile Games Industry

Written by Ι Stock Market Media — March 2, 2016

SPYR, Inc. (OTCQB: SPYR) has been busy in the mobile game & app development and publishing industry since it entered the space almost a year ago. With plenty of news already coming from the Denver tech firm in 2016, Stock Market Media Group (SMMG), a research and content development investment relations firm, caught up with Paul Thind, SPYR’s Managing Director of Games & Applications, while he attended the Casual Connect conference in Amsterdam, ...

Read More →
0

Johnson & Johnson and Big Pharma Could Find a Diabetes “Cure” with PharmaCyte Biotech’s Type 1 Diabetes Treatment

Johnson & Johnson and Big Pharma Could Find a Diabetes “Cure” with PharmaCyte Biotech’s Type 1 Diabetes Treatment

Written by Ι Stock Market Media — February 8, 2016

Johnson & Johnson, like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, Johnson & Johnson’s head of global innovation, said that his company’s recent decision to partner with a privately held San Diego biotech was to “hedge our bets to make sure we would win in this space.” Johnson & Johnson’s deal with ViaCyte, Inc. is an effort to ...

Read More →
0

Tech Newcomer, SPYR, Inc. Expands Reach in Fast Growing Global Games Market

Tech Newcomer, SPYR, Inc. Expands Reach in Fast Growing Global Games Market

Written by Ι Stock Market Media — January 27, 2016

SPYR, Inc. (OTCQB: SPYR) has proven it will employ an “all-of-the-above” strategy when it comes to growing its footprint in the multi-billion dollar mobile games market. 2016 is barely underway, and SPYR has already made two interesting announcements that show the company isn’t afraid to get creative to broaden its opportunity for success.

The first came in early January when the company launched “Retro Shot,” in select overseas markets for testing. The new mobile ...

Read More →
0

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

PharmaCyte Biotech Outlines 2016 Milestones as Company Moves Into Cancer Clinical Trial

SILVER SPRING, Md., Jan. 06, 2016 — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today the Company’s 2016 milestones as it advances its new treatment for pancreatic cancer into the clinic in the United States with study sites in Europe and Australia.

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 ...

Read More →
0
Page 5 of 31 «...34567...»
ContactUs.com ContactUs.com